IRF1 and psoriasis: The identification of IRF1, a dual regulator of autophagy and apoptosis in response to bevacizumab treatment,79 as one of the top activated upstream regulators in non‐lesional skin, re‐enforces the hypothesis that IRF1 mediates the anti‐apoptotic effect of bevacizumab in non‐lesional psoriasis skin.